Common drugs tested to fight silent fatty liver epidemic
NCT ID NCT07338331
Summary
This study tested whether daily low-dose aspirin or the diabetes drug empagliflozin (an SGLT2 inhibitor) could improve liver health in people with type 2 diabetes and fatty liver disease. For 6 months, 80 participants took one of the medications. Researchers measured changes in liver enzymes, cholesterol, liver stiffness, and body weight to see which treatment was more helpful.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Faculty of Pharmacy
Banī Suwayf, Beni Suweif Governorate, 0000, Egypt
Conditions
Explore the condition pages connected to this study.